Comparative Pharmacology
Head-to-head clinical analysis: PARACORT versus UCERIS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PARACORT versus UCERIS.
PARACORT vs UCERIS
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Paracort is a corticosteroid that acts by binding to glucocorticoid receptors, leading to modulation of gene expression and suppression of inflammatory mediators such as cytokines and prostaglandins.
Uceris (budesonide) is a corticosteroid with potent glucocorticoid activity. It binds to the glucocorticoid receptor, leading to inhibition of pro-inflammatory cytokines (e.g., IL-1, IL-2, IL-4, IL-5, TNF-alpha), suppression of arachidonic acid metabolism via phospholipase A2 inhibition, and reduction of inflammatory cell infiltration. It has high topical anti-inflammatory activity and undergoes extensive first-pass hepatic metabolism, minimizing systemic bioavailability.
Inflammatory conditions (e.g., rheumatoid arthritis, asthma)Allergic disordersDermatological diseasesEndocrine disorders (e.g., adrenal insufficiency)Neoplastic conditions (e.g., leukemia, lymphoma)
Induction of remission in patients with active, mild to moderate ulcerative colitisOff-label: Treatment of Crohn's disease (ileocecal involvement), microscopic colitis, and graft-versus-host disease
Prednisone 5-60 mg orally once daily; initial dose 5-15 mg daily; for acute conditions, up to 60 mg daily tapered over 2-3 weeks.
For induction of remission in mild to moderate active ulcerative colitis: one 9 mg extended-release tablet orally once daily for up to 8 weeks.
None Documented
None Documented
Terminal elimination half-life is 3.5 hours (range 2.5–4.5 hours) in adults with normal renal function; prolonged to up to 10–15 hours in severe renal impairment (CrCl <30 mL/min).
2.8-4.5 hours (terminal). Clinical context: short half-life supports once-daily extended-release formulation for colonic delivery.
Primarily hepatic via CYP3A4; also involves 11β-hydroxysteroid dehydrogenase.
Hepatic metabolism primarily via cytochrome P450 3A4 (CYP3A4) to inactive metabolites (e.g., 6β-hydroxybudesonide, 16α-hydroxyprednisolone). Extensive first-pass effect; approximately 90% of absorbed dose is metabolized before reaching systemic circulation.
Renal elimination of unchanged drug accounts for approximately 70% of the dose; biliary/fecal excretion accounts for 20%; the remainder is metabolized and excreted as inactive metabolites.
Renal: <1%. Fecal: approximately 63% as budesonide and metabolites. Biliary: minor.
90–95% bound to albumin and alpha-1-acid glycoprotein.
85-90% bound primarily to albumin.
1.5 L/kg (range 1.2–1.8 L/kg); indicates extensive extravascular distribution and tissue binding.
2.2-4.3 L/kg, indicating extensive tissue distribution.
Oral: 85–95% (well absorbed; minimal first-pass metabolism); Intramuscular: 90–100%; Rectal: 60–70%.
Oral extended-release: approximately 9% (systemic) due to high first-pass metabolism. Rectal foam: approximately 15% (systemic).
No adjustment required for mild to moderate renal impairment. For severe renal impairment (GFR <30 mL/min): use with caution and monitor for fluid retention. No specific dose adjustment guidelines.
No dose adjustment required for mild-to-moderate renal impairment. Not studied in severe renal impairment (CrCl <30 mL/min); use with caution.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50% due to impaired corticosteroid metabolism. Child-Pugh C: avoid or use with extreme caution; consider alternative glucocorticoid.
Contraindicated in patients with severe hepatic impairment (Child-Pugh Class C). For moderate hepatic impairment (Child-Pugh Class B), use with caution; no specific dose adjustment recommended. For mild impairment (Child-Pugh Class A), no adjustment needed.
Oral: 0.1-2 mg/kg/day in divided doses every 6-12 hours; typical starting dose 1-2 mg/kg/day for anti-inflammatory effect; maximum 60 mg/day. For asthma: 1-2 mg/kg/day for 3-5 days.
Not approved for use in pediatric patients. Safety and efficacy not established in children under 18 years.
Elderly patients: initiate at lower end of dosing range (5-10 mg/day) due to increased risk of osteoporosis, hypertension, and diabetes; taper slowly; monitor for glucose intolerance, fluid retention, and adrenal suppression.
No specific dose adjustment recommended. Elderly patients may be more susceptible to adverse effects such as hypercorticism and adrenal suppression; monitor closely.
None FDA-approved. However, long-term use may suppress hypothalamic-pituitary-adrenal (HPA) axis and increase infection risk.
None
["Immunosuppression and increased infection risk","Adrenal suppression with prolonged use","Osteoporosis with long-term therapy","Hyperglycemia and diabetes mellitus","Gastrointestinal perforation risk"]
Hypercorticism and adrenal suppression (especially at higher doses, prolonged use, or co-administration with CYP3A4 inhibitors); increased risk of infections (including reactivation of tuberculosis, fungal, bacterial, viral, or parasitic infections); corticosteroid withdrawal symptoms upon abrupt discontinuation; gastrointestinal perforation risk in patients with active ulcers, diverticulitis, or recent intestinal anastomosis; osteoporosis and bone density loss with long-term use; glaucoma, cataracts, and increased intraocular pressure; inhibition of growth in pediatric patients; exacerbation of diabetes mellitus and hypertension.
["Systemic fungal infections","Hypersensitivity to paracort or any component","Use of live vaccines"]
Hypersensitivity to budesonide or any component of the formulation; patients with active or latent tuberculosis; untreated systemic fungal, bacterial, viral, or parasitic infections; patients receiving live or live-attenuated vaccines (due to immunosuppression); patients with severe hepatic impairment (Child-Pugh Class C) because of decreased metabolism and increased systemic exposure.
Data Pending Review
Data Pending Review
Avoid grapefruit and grapefruit juice as they may increase drug levels. Limit high-sodium foods to reduce fluid retention. Take with a meal to minimize gastrointestinal irritation.
Avoid grapefruit and grapefruit juice, as they inhibit CYP3A4 and increase budesonide systemic exposure. No other significant food interactions documented. Can be taken with or without food.
First trimester: Increased risk of orofacial clefts (odds ratio 1.3–3.4) and cardiovascular defects (odds ratio 1.5–2.0). Second/third trimesters: Risk of intrauterine growth restriction, preterm birth, and adrenal suppression in the neonate. Chronic use: Increased risk of premature rupture of membranes.
Uceris (budesonide) is a corticosteroid. In pregnant women, first-trimester exposure may be associated with a small increased risk of oral clefts (absolute risk about 1 in 1000). Second and third trimester exposure may increase risk of fetal growth restriction and adrenal suppression in the newborn. Animal studies show fetal harm at clinically relevant doses. Use only if benefit outweighs risk.
Enters breast milk; M/P ratio approximately 0.3. Low doses (≤20 mg/day prednisone equivalent) considered compatible. High doses may cause infant adrenal suppression; monitor infant growth. Avoid breastfeeding within 4 hours of dose.
Budesonide is excreted into human milk in low amounts; the milk-to-plasma ratio is approximately 0.4. Estimated infant daily dose is less than 1% of maternal weight-adjusted dose. No adverse effects reported. Caution advised with higher maternal doses or prolonged use. Consider using the lowest effective dose.
Increased clearance in pregnancy may require dose increase of 20-30% to maintain therapeutic effect. Use lowest effective dose. For adrenal insufficiency, increase glucocorticoid dose 20-40% in third trimester and during labor (stress dosing).
No specific dose adjustment required during pregnancy based on pharmacokinetic changes. Use the lowest effective dose for the shortest duration. Standard Uceris dosing (9 mg once daily) can be used; if clinical response is inadequate, consider alternative therapies.
Category C
Category C
Paracort is a brand name for prednisolone. Monitor for hyperglycemia, especially in diabetic patients. Taper dose to avoid adrenal crisis. Corticosteroids may mask signs of infection. Use lowest effective dose for shortest duration.
UCERIS (budesonide) is a locally-acting corticosteroid with high first-pass hepatic metabolism, minimizing systemic absorption. It is effective for inducing remission in mild-to-moderate ulcerative colitis (UC). Extended-release formulation targets the ileum and ascending colon. Not effective for acute severe UC. Taper dose gradually to avoid adrenal insufficiency. Monitor for corticosteroid effects (e.g., hyperglycemia, osteoporosis) with prolonged use.
Take with food to reduce stomach upset.Do not stop suddenly; dose must be tapered.Report signs of infection (fever, sore throat) immediately.Avoid live vaccines while on this medication.Carry a steroid warning card or ID.
Take UCERIS exactly as prescribed, usually once daily in the morning.Swallow the tablet whole; do not crush, chew, or break it.Avoid grapefruit and grapefruit juice during treatment as they increase drug levels.Report any signs of infection (fever, sore throat) or worsening symptoms.Do not stop abruptly; dose must be tapered under doctor's supervision.Inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding.Keep a record of your bowel movements and symptoms to monitor response.